<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="data and current knowledge of secondary bacterial infections and their" exact="treatment" post="in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV,"/>
 <result pre="antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial" exact="infection" post="pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic"/>
 <result pre="MERS-CoV: 2012–2020; Ebola virus: 2013–2016; Zika virus: 2015–2016; SARS-CoV-2: 2019-present)," exact="infection" post="with four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2)"/>
 <result pre="or following initial infection. In addition, co-infections - the simultaneous" exact="infection" post="with a second pathogen of viral or bacterial origin-"/>
 <result pre="1B) (6, 7). Figure 1 (A) Possible disease progression after" exact="infection" post="with a respiratory virus. (B) Overview of case reports"/>
 <result pre="virus. (B) Overview of case reports of all respiratory virus" exact="infection" post="data reviewed in this study, including rate of secondary"/>
 <result pre="alter the immunity to other infectious agent(s), resulting in increased" exact="prevalence" post="of viral-induced secondary bacterial infections (10). Mammalian cells are"/>
 <result pre="attachment and colonization when infected by a virus (11, 12);" exact="infection" post="with respiratory syncytial virus (RSV), rhinovirus and influenza virus"/>
 <result pre="During active viral infections, the route of infection, proximity of" exact="infection" post="as well as virulence factors varies between bacterial strains"/>
 <result pre="factors varies between bacterial strains resulting in different outcomes. Effective" exact="treatment" post="of both the viral and the secondary bacterial infection(s)"/>
 <result pre="initially do not treat secondary bacterial infections (15). The preferred" exact="treatment" post="for bacterial infections is generally broad-spectrum antibiotics, but this"/>
 <result pre="Carbapenem-resistant Acinetobacter baumannii (20). If a patient with a viral" exact="infection" post="is unfortunate to become infected by MDR bacteria, no"/>
 <result pre="is unfortunate to become infected by MDR bacteria, no standard" exact="treatment" post="is currently available. In one COVID-19 cohort study, described"/>
 <result pre="meropenem and linezolid to children with a rate of prophylactic" exact="treatment" post="between 19.4 and 100.0% (24). In adults mainly quinolones,"/>
 <result pre="In adults mainly quinolones, cephalosporins and macrolides were used for" exact="treatment" post="with rates of prophylaxis between 13.2 and 100.0%. In"/>
 <result pre="COVID-19 requiring hospitalization and critical care. Early stages of SARS-CoV-2" exact="infection" post="typically include symptoms of mild fever and shortness of"/>
 <result pre="may result in pneumonia. In almost all severe cases, SARS-CoV-2" exact="infection" post="results in pneumonia and the inflamed fluid-filled alveolar tissue"/>
 <result pre="of secondary bacterial infections in those infected with SARS-CoV-2 complicates" exact="treatment" post="(26, 27). An overview of all COVID-19 case studies,"/>
 <result pre="Information, where we have analyzed 15 case studies reporting SARS-CoV-2" exact="infection" post="(Supplemental Data Sheet 1). In particular for data obtained"/>
 <result pre="risk of nosocomial infections, a prophylactic strategy. Should a bacterial" exact="infection" post="occur despite the prophylactic use of antibiotics, caused by"/>
 <result pre="of superinfection with MDR bacteria poses additional challenges for the" exact="treatment" post="of severely sick COVID-19 patients in intensive care units"/>
 <result pre="in China, were examined to provide information of the occurrence," exact="treatment" post="of or prophylactic measures for bacterial secondary infections during"/>
 <result pre="(25, 26, 29, 36, 38). Three studies reported therapeutic antibiotic" exact="treatment" post="in 92 of 146 patients (63%), which were administered"/>
 <result pre="prophylactic antibiotic therapy (48, 50–53). The antibiotics used for prophylactic" exact="treatment" post="were levofloxacin, clarithromycin, amoxicillin-clavulanic acid, piperacillin-tazobactum, maxipime, azithromycin, amoxicillin-clavulanate,"/>
 <result pre="= 866), the highest among all coronavirus diseases (52). The" exact="infection" post="often starts as a mild viral respiratory illness but"/>
 <result pre="commonly deployed with secondary bacterial infections rarely occurring under this" exact="treatment" post="regime (53–55). Here, we review MERS-related case studies, outlining"/>
 <result pre="antibiotics (55, 56, 58, 59). The development of secondary bacterial" exact="infection" post="was reported in two studies, with 32 of 82"/>
 <result pre="VRE and S. pneumoniae. No detailed report was provided about" exact="treatment" post="antibiotics and one study reported (patients n = 15)"/>
 <result pre="influenza viruses and secondary bacterial infections (Supplementary File). Details on" exact="treatment" post="and disease progression of a total of 910 patients"/>
 <result pre="cephalosporin (65). In general, all eight case studies reported the" exact="treatment" post="complications due to secondary bacterial infections. Discussion The lack"/>
 <result pre="antibiotic-resistant bacterial infections are increasing, providing such data of secondary" exact="infection" post="is important, almost critical. Clinical reports are a valuable"/>
 <result pre="bacterial pathogen, but rather target pathogen-intrinsic components important for the" exact="infection" post="process. These include bacterial components such as exo- and"/>
 <result pre="https://www.frontiersin.org/articles/10.3389/fmed.2020.00420/full#supplementary-material Supplementary Figure 1 Overview of case reports of SARS-CoV-2" exact="infection" post="data reviewed in this study, including rate of secondary"/>
 <result pre="Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced secondary bacterial" exact="infection" post="in COPD: a concise review. Front Immunol. (2018) 9:2345."/>
 <result pre="concise review. Front Immunol. (2018) 9:2345. 10.3389/fimmu.2018.0234530459754 4.MalliaPFootittJSoteroRJepsonAContoliMTrujillo-TorralboMBet al.. Rhinovirus" exact="infection" post="induces degradation of antimicrobial peptides and secondary bacterial infection"/>
 <result pre="Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial" exact="infection" post="in chronic obstructive pulmonary disease. Am J Respir Crit"/>
 <result pre="10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and secondary bacterial" exact="infection" post="in fatal and serious outcomes of pandemic influenza a"/>
 <result pre="pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505 8.KimYGParkJHReimerTBakerDPKawaiTKumarHet al.. Viral" exact="infection" post="augments Nod1/2 signaling to potentiate lethality associated with secondary"/>
 <result pre="PLoS Neglect Trop D. (2017) 11:e0005901. 10.1371/journal.pntd.000590128886013 12.PittetLAHall-StoodleyLRutkowskiMRHarmsenAG. Influenza virus" exact="infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae."/>
 <result pre="Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial" exact="infection" post="in scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963"/>
 <result pre="J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary bacterial" exact="infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients."/>
 <result pre="Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza virus" exact="infection" post="pathogenesis in influenza pathogenesis and control. Curr Top Microbiol"/>
 <result pre="Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical management and" exact="infection" post="control of SARS: lessons learned. Antiviral Res. (2013) 100:407–19."/>
 <result pre="Med. (2004) 128:195–204. 10.1043/1543-2165(2004)128&amp;lt;195:AODDTS&amp;gt;2.0.CO;214736283 46.SoLKLauACYamLYCheungTMPoonEYungRWet al.. Development of a standard" exact="treatment" post="protocol for severe acute respiratory syndrome. Lancet. (2003) 361:1615–7."/>
 <result pre="study. Lancet. (2003) 361:1767–72. 10.1016/S0140-6736(03)13412-512781535 50.ZhaoZZhangFXuMHuangKZhongWCaiWet al.. Description and clinical" exact="treatment" post="of an early outbreak of severe acute respiratory syndrome"/>
 <result pre="(2003) 52:715–20. 10.1099/jmm.0.05320-012867568 51.WangJTShengWHFangCTChenYCWangJLYuCJet al.. Clinical manifestations, laboratory findings, and" exact="treatment" post="outcomes of SARS patients. Emerg Infect Dis. (2004) 10:818–24."/>
 <result pre="10.1056/NEJMoa130372923718156 60.Available, online at: https://www.cdc.gov/flu/about/viruses/types.htm 61.https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/ 62.McCullersJA. Effect of antiviral" exact="treatment" post="on the outcome of secondary bacterial pneumonia after influenza."/>
</results>
